Famitinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: In combination with camrelizumab for recurrent or metastatic cervical cancer (conditional... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Cervical Cancer · Phase 3 · investigational in the US

Also approved (1)
CN
  • In combination with camrelizumab for recurrent or metastatic cervical cancer (conditional approval)
Product first approved 2025ebi.ac.uk

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (10)
Cervical Cancer
NCT04906993 · Jiangsu HengRui Medicine Co., Ltd.
2021-07-23 – 2027-05-31 · Cervical Cancer
What this study did
Non-Small Cell Lung Cancer
NCT04619433 · Jiangsu HengRui Medicine Co., Ltd.
2021-02-01 – 2025-08-16 · Non-squamous Non-small-cell Lung Cancer
What this study did
NCT05106335 · Jiangsu HengRui Medicine Co., Ltd.
2022-01-06 – 2022-05-11 · Advanced NSCLC
What this study did
NCT02766140 · Jiangsu HengRui Medicine Co., Ltd.
2016-06 – 2016-11 · Non Squamous Non Small Cell Lung
What this study did
Other / comorbidity
NCT05999149 · Fudan University
2023-08-20 – 2027-08-30 · TNBC - Triple-Negative Breast Cancer
What this study did
NCT06913777 · Fudan University
2025-04-08 – 2027-04-15 · Neoadjuvant Therapy
What this study did
NCT05760378 · Fudan University
2023-03-17 – 2027-01-01 · Triple-Negative Breast Cancer
What this study did
NCT04409223 · Jiangsu HengRui Medicine Co., Ltd.
2020-09-12 – 2022-03-25 · Gastrointestinal Stromal Tumors
What this study did
NCT02390947 · Jiangsu HengRui Medicine Co., Ltd.
2015-01 – 2019-07 · Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
What this study did
Phase 2 (44)
Cervical Cancer
NCT07627620 · Hunan Cancer Hospital
2026-06-30 – 2029-03-30 · Cervical Cancer
What this study did
NCT03827837 · Jiangsu HengRui Medicine Co., Ltd.
2019-01-23 – 2022-12 · Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent, Endometrial Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06336954 · Second Affiliated Hospital of Xi'an Jiaotong University
2024-03-30 – 2026-12-31 · Non Small Cell Lung Cancer
What this study did
NCT06332300 · Jiangsu Province Nanjing Brain Hospital
2024-02-01 – 2026-02-01 · NSCLC
What this study did
NCT05005468 · Shanghai Chest Hospital
2021-09 – 2024-08 · NSCLC
What this study did
NCT03904823 · Jiangsu HengRui Medicine Co., Ltd.
2019-04-25 – 2022-12 · EGFR-mutant Non-Small Cell Lung Cancer
What this study did
NCT04699968 · Jiangsu HengRui Medicine Co., Ltd.
2021-01-15 – 2021-11-15 · Non-Small-Cell Lung Cancer
What this study did
NCT02356991 · Jiangsu HengRui Medicine Co., Ltd.
2014-12 – 2020-06 · Non-Small Cell Lung Cancer (NSCLC)
What this study did
Other / comorbidity
NCT07382713 · Jinhua Zhou
2026-02-28 – 2030-12-31 · Ovarian Cancer
What this study did
NCT05582499 · Fudan University
2022-11-01 – 2029-09 · Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07814859 · The First Affiliated Hospital of Zhengzhou University
2026-08-31 – 2029-08-31 · Pancreatic Cancer
What this study did
NCT07847710 · The First Affiliated Hospital with Nanjing Medical University
2026-09-30 – 2029-03-01 · Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy
What this study did
NCT05749588 · Fudan University
2023-03-30 – 2028-12-31 · Triple-negative Breast Cancer
What this study did
NCT07517653 · Shanghai Zhongshan Hospital
2026-04-01 – 2028-12-30 · Melanoma
What this study did
NCT07796113 · First Affiliated Hospital Xi'an Jiaotong University
2025-10-30 – 2028-10-30 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07309185 · Shandong Tumor Hospital
2024-07-24 – 2028-07-31 · Stomach Neoplasms
What this study did
NCT07147088 · Fudan University
2025-09-01 – 2027-09-01 · Advanced Intrahepatic Cholangiocarcinoma
What this study did
NCT06649331 · Fudan University
2024-10-21 – 2027-09 · Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast Cancer
What this study did
NCT06516289 · Fudan University
2024-09-30 – 2027-06 · BRCA-Mutated Breast Carcinoma, HER2-negative Breast Cancer
What this study did
NCT06306560 · Harbin Medical University
2024-03-15 – 2027-04-15 · Extensive-stage Small-cell Lung Cancer
What this study did
NCT05594095 · Fudan University
2022-12-30 – 2026-12-01 · Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
NCT04888429 · Qian Chu
2021-07-19 – 2025-06-30 · Sarcomatoid Carcinoma of Lung
What this study did
NCT06146985 · Ruijin Hospital
2023-12-01 – 2025-05-01 · Thyroid Cancer
What this study did
NCT04355858 · Fudan University
2020-05-01 – 2025-04-01 · Breast Cancer, Metastatic Cancer
What this study did
NCT04395989 · Fudan University
2020-07-28 – 2024-12-31 · TNBC - Triple-Negative Breast Cancer
What this study did
NCT05051865 · Peking University Cancer Hospital & Institute
2021-10-09 – 2024-08-30 · Melanoma
What this study did
NCT04733417 · Tianjin Medical University Cancer Institute and Hospital
2021-05-26 – 2023-09-30 · Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT05670925 · Fudan University
2023-03-01 – 2023-09-01 · Triple-Negative Breast Cancer
What this study did
NCT05214976 · Jiangsu HengRui Medicine Co., Ltd.
2022-08-12 – 2023-07-31 · Advanced Solid Tumors
What this study did
NCT04814485 · Tianjin Medical University Cancer Institute and Hospital
2021-04-22 – 2023-07 · Pancreatic Cancer
What this study did
NCT04866381 · Tianjin Medical University Cancer Institute and Hospital
2021-04 – 2023-04 · Esophageal Squamous Cell Carcinoma, Progression to PD-1 Antibody
What this study did
NCT04884009 · Jiangsu HengRui Medicine Co., Ltd.
2021-05-31 – 2022-12-31 · Lung Cancer
What this study did
NCT04346381 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-05 – 2022-06-22 · Solid Tumor
What this study did
NCT04479904 · Jiangsu HengRui Medicine Co., Ltd.
2020-08-10 – 2022-02-10 · Intrahepatic Cholangiocarcinoma
What this study did
NCT02336724 · Jiangsu HengRui Medicine Co., Ltd.
2012-03 – 2019-06 · Gastrointestinal Stromal Tumor
What this study did
NCT01392235 · Jiangsu HengRui Medicine Co., Ltd.
2011-07 – 2016-08 · Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
What this study did
NCT01994213 · Jiangsu HengRui Medicine Co., Ltd.
2011-10 – 2016-05 · Gastroenteropancreatic Neuroendocrine Tumor
What this study did
NCT01829841 · Jiangsu HengRui Medicine Co., Ltd.
2011-05 – 2016-05 · Renal Cell Cancer, Metastatic Renal Cell Cancer
What this study did
NCT01762293 · Jiangsu HengRui Medicine Co., Ltd.
2012-04 – 2014-10 · Colorectal Cancer, Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
What this study did
Phase 1/2 (5)
Other / comorbidity
NCT07662681 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2026-07-01 – 2029-07-01 · Head and Neck Cancer
What this study did
NCT06332950 · Baohui Han
2024-04-01 – 2027-04-01 · Extensive-stage Small-cell Lung Cancer
What this study did
NCT05176080 · Henan Cancer Hospital
2021-12-08 – 2024-07-03 · Metastatic Breast Cancer
What this study did
NCT05020925 · Jiangsu HengRui Medicine Co., Ltd.
2021-09 – 2024-02 · Nasopharyngeal Carcinoma
What this study did
NCT04679038 · Jiangsu HengRui Medicine Co., Ltd.
2021-03-17 – 2023-10-01 · Solid Tumor
What this study did
Phase 1 (11)
Non-Small Cell Lung Cancer
NCT02364362 · Jiangsu HengRui Medicine Co., Ltd.
2015-01 – 2018-12 · Non-Small Cell Lung Cancer (NSCLC)
What this study did
Other / comorbidity
NCT05103826 · Jiangsu HengRui Medicine Co., Ltd.
2021-10-25 – 2023-06-15 · ER+ / HER2- Advanced Breast Cancer
What this study did
NCT05473468 · Jiangsu HengRui Medicine Co., Ltd.
2022-08-26 – 2022-11 · Healthy Subjects
What this study did
NCT05336279 · Jiangsu HengRui Medicine Co., Ltd.
2022-05-11 – 2022-06-20 · Solid Tumor
What this study did
NCT05147727 · Jiangsu HengRui Medicine Co., Ltd.
2022-03-14 – 2022-05-02 · Tumor
What this study did
NCT05046808 · Jiangsu HengRui Medicine Co., Ltd.
2021-09-23 – 2021-11-22 · Solid Tumor
What this study did
NCT05041920 · Jiangsu HengRui Medicine Co., Ltd.
2021-09-07 – 2021-10-27 · Tumor
What this study did
NCT04494659 · Jiangsu HengRui Medicine Co., Ltd.
2020-07-20 – 2020-08-31 · Healthy Adult Subjects
What this study did
NCT04400123 · Jiangsu HengRui Medicine Co., Ltd.
2020-05-27 – 2020-07-18 · Healthy Adult Subjects
What this study did
NCT01462474 · Jiangsu HengRui Medicine Co., Ltd.
2011-10 – 2016-01 · Locally Advanced Nasopharyngeal Carcinoma
What this study did
NCT01762280 · Jiangsu HengRui Medicine Co., Ltd.
2009-06 – 2012-07 · Advanced Solid Tumor
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1/2 (1)
Other / comorbidity
NCT04044378 · Peking University People's Hospital
2019-08-15 – 2022-09-30 · Effect of Drugs, Progression, Pediatric Cancer
What this study did

Competitive landscape

This drug's own stage for Cervical Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Famitinib: this drugPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tisotumab Vedotin Humax-Tf-Adc (Tivdak)ApprovedAntibody–drug conjugateTissue Factor (TF)Partial signal
NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7)
NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sutantatug EnvedotinPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
ALE.P02
Phase 1/2(overall)
Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Famitinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT07143292 · CT.gov ↗
What to watch
2027 (8)
March 2027 (1)
Phase 2Extensive-stage Small-cell Lung CancerNot yet recruiting
Est. primary completion 2027-03-15 · NCT06306560 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1/2Extensive-stage Small-cell Lung CancerNot yet recruiting
Est. primary completion 2027-04-01 · NCT06332950 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Stomach NeoplasmsRecruiting
Est. primary completion 2027-07-31 · NCT07309185 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2027-08-31 · NCT07814859 · CT.gov ↗
What to watch
September 2027 (2)
Phase 2Advanced Intrahepatic CholangiocarcinomaNot yet recruiting
Est. primary completion 2027-09-01 · NCT07147088 · CT.gov ↗
What to watch
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2027-09-30 · NCT07627620 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05749588 · CT.gov ↗
What to watch
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
2028 (6)
March 2028 (1)
Phase 2Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant TherapyRecruiting
Est. primary completion 2028-03-01 · NCT07847710 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1/2Head and Neck CancerRecruiting
Est. primary completion 2028-07-01 · NCT07662681 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-10-30 · NCT07796113 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2MelanomaNot yet recruiting
Est. primary completion 2028-11-30 · NCT07517653 · CT.gov ↗
What to watch
December 2028 (2)
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2028-12-30 · NCT07355010 · CT.gov ↗
What to watch
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07382687 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2030-12-31 · NCT07382713 · CT.gov ↗
What to watch

See the full readout calendar ↗